Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report
| Autor: | Xanthi Yiakoumis, Dimitra Rontogianni, Sotirios Sachanas, Christina Kalpadakis, Gerassimos A. Pangalis, Petros Karouzakis, Maria Moschogiannis, Efstathios Koulieris |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chronic lymphocytic leukemia medicine.medical_treatment Urinary Bladder medicine.disease_cause Hypogammaglobulinemia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Piperidines Agammaglobulinemia hemic and lymphatic diseases Internal medicine medicine Humans Aged Immunosuppressive effect Immunosuppression Therapy Urinary bladder business.industry Adenine Malacoplakia Malakoplakia Immunosuppression General Medicine Immune dysregulation medicine.disease Leukemia Lymphocytic Chronic B-Cell Pyrimidines medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Ibrutinib Pyrazoles Female Chromosome Deletion business Chromosomes Human Pair 17 030215 immunology |
| Zdroj: | Anticancer Research. 36:4759-4762 |
| ISSN: | 0250-7005 |
| DOI: | 10.21873/anticanres.11032 |
| Popis: | Malakoplakia, a rare granulomatous disease of infectious etiology, is commonly observed in immunocompromised patients. Chronic lymphocytic leukemia (CLL) is characterized by profound immune dysregulation resulting in significant infection-related morbidity and mortality, and several drugs used in CLL treatment have a severe immunosuppressive effect. Ibrutinib, has become a new standard-of-care in patients with CLL, especially for those harboring unfavorable genetic characteristics such as 17 p deletion, with however, unknown long-term immunological consequences. Here we report a case of a patient with CLL with 17 p deletion diagnosed with malakoplakia of the urinary bladder under ibrutinib therapy who developed severe hypogammaglobulinemia during treatment administration. Presumably, ibrutinib might contribute to the development of malakoplakia on the grounds of induced immunosuppression. This case report highlights the need for regular assessment of immunogammaglobulin adequacy during treatment with ibrutinib, considering that it should be given on a permanent basis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|